Janux Therapeutics, Inc. (JANX)
Largest Insider Buys in Sector
JANX Stock Price History Chart
JANX Stock Performance
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against …
Insider Activity of Janux Therapeutics, Inc.
Over the last 12 months, insiders at Janux Therapeutics, Inc. have bought $53.7M and sold $340.04M worth of Janux Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Janux Therapeutics, Inc. have bought $60.64M and sold $120.41M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $1.61B.
The last purchase of 1,200,000 shares for transaction amount of $53.7M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑10‑18.
List of Insider Buy and Sell Transactions, Janux Therapeutics, Inc.
| 2024-12-03 | Sale | President and CEO | 15,000 0.0317% | $67.00 | $1M | +2.99% | ||
| 2024-11-25 | Sale | President and CEO | 25,000 0.0505% | $51.60 | $1.29M | +25.57% | ||
| 2024-10-28 | Sale | President and CEO | 25,000 0.0486% | $53.54 | $1.34M | +1.60% | ||
| 2024-10-18 | Sale | 10 percent owner | 1.46M 2.5633% | $45.76 | $66.9M | +8.36% | ||
| 2024-10-18 | 1.2M 2.0576% | $44.75 | $53.7M | +8.36% | ||||
| 2024-10-17 | Sale | 10 percent owner | 1,843 0.0035% | $50.02 | $92,187 | +8.83% | ||
| 2024-10-16 | Sale | 10 percent owner | 209,516 0.4311% | $50.03 | $10.48M | +9.71% | ||
| 2024-09-30 | Sale | 10 percent owner | 958 0.0018% | $46.24 | $44,298 | +14.44% | ||
| 2024-09-27 | Sale | President and CEO | 25,000 0.0476% | $46.31 | $1.16M | +10.79% | ||
| 2024-09-27 | Sale | Chief Scientific Officer | 5,000 0.0095% | $46.34 | $231,716 | +10.79% | ||
| 2024-09-27 | Sale | Chief Business Officer | 50,000 0.0945% | $45.96 | $2.3M | +10.79% | ||
| 2024-09-27 | Sale | 10 percent owner | 106,821 0.2041% | $46.46 | $4.96M | +10.79% | ||
| 2024-09-26 | Sale | 10 percent owner | 200,000 0.3603% | $47.23 | $9.45M | -0.89% | ||
| 2024-09-13 | Sale | 10 percent owner | 3,815 0.0068% | $46.68 | $178,084 | +0.38% | ||
| 2024-09-12 | Sale | 10 percent owner | 350,000 0.6777% | $47.00 | $16.45M | +7.70% | ||
| 2024-09-10 | Sale | 10 percent owner | 101,091 0.1981% | $46.53 | $4.7M | +9.91% | ||
| 2024-09-09 | Sale | 10 percent owner | 2,182 0.0042% | $42.33 | $92,364 | +19.52% | ||
| 2024-09-06 | Sale | 10 percent owner | 240,000 0.4683% | $42.00 | $10.08M | +21.21% | ||
| 2024-06-03 | Sale | Acting Chief Financial Officer | 822,721 1.5801% | $54.75 | $45.04M | -15.86% | ||
| 2024-06-03 | Sale | 1.5M 2.8808% | $54.75 | $82.13M | -15.86% |
Insider Historical Profitability
| RA CAPITAL MANAGEMENT, L.P. | 9317246 16.1199% | $56.83 | 3 | 0 | +1.61% | |
| Reardon Tighe | Acting Chief Financial Officer | 633673 1.0963% | $56.83 | 2 | 1 | +1.61% |
| Avalon Ventures XI, L.P. | 10 percent owner | 401321 0.6943% | $56.83 | 2 | 11 | +1.61% |
| Lichter Jay | 10 percent owner | 7000 0.0121% | $56.83 | 2 | 2 | +1.61% |
| Bregua Corp | 10 percent owner | 3749250 6.4866% | $56.83 | 1 | 0 | +1.61% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $345.09M | 17.68 | 9.17M | 0% | +$0 | 0.35 | |
| Fidelity Investments | $291.75M | 14.95 | 7.75M | +65.89% | +$115.88M | 0.02 | |
| OrbiMed | $160.97M | 8.25 | 4.28M | +28.86% | +$36.05M | 1.24 | |
| Bvf Inc Il | $109.93M | 5.63 | 2.92M | -36.25% | -$62.5M | 0.81 | |
| Adage Capital Partners Gp L L C | $104.5M | 5.35 | 2.78M | +104.78% | +$53.47M | 0.19 |